Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Amylyx Pharmaceuticals Inc (AMLX)

Amylyx Pharmaceuticals Inc (AMLX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,710,920
  • Shares Outstanding, K 58,533
  • Annual Sales, $ 290 K
  • Annual Income, $ -87,930 K
  • 60-Month Beta N/A
  • Price/Sales 5,947.77
  • Price/Cash Flow N/A
  • Price/Book 8.79
Trade AMLX with:

Options Overview Details

View History
  • Implied Volatility 144.08% ( -6.52%)
  • Historical Volatility 155.59%
  • IV Percentile 54%
  • IV Rank 22.09%
  • IV High 326.69% on 03/29/22
  • IV Low 92.29% on 03/31/22
  • Put/Call Vol Ratio 0.42
  • Today's Volume 1,369
  • Volume Avg (30-Day) 9,568
  • Put/Call OI Ratio 0.65
  • Today's Open Interest 71,503
  • Open Int (30-Day) 68,293

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.94
  • Number of Estimates 2
  • High Estimate -0.93
  • Low Estimate -0.96
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.80 +89.78%
on 09/02/22
32.80 -8.58%
on 09/08/22
+4.49 (+17.59%)
since 08/29/22
3-Month
15.80 +89.78%
on 09/02/22
32.80 -8.58%
on 09/08/22
+11.81 (+64.93%)
since 06/29/22

Most Recent Stories

More News
3 IPO Stocks That You Want to Own

This down market is giving us some really intriguing stocks at cheap prices.

AMLX : 29.77 (+1.85%)
HLVX : 19.32 (-3.83%)
DCGO : 9.88 (-4.26%)
TAK : 12.94 (-0.99%)
Biotech Stock Roundup: BMY Surges on Drug Approval, REGN Up on Update & More

Regulatory and pipeline updates from BMY and REGN are the key highlights from the biotech sector during the past week.

REGN : 689.22 (-2.30%)
BMY : 71.22 (-1.17%)
NVAX : 18.33 (-6.53%)
AMLX : 29.77 (+1.85%)
AKRO : 29.29 (+1.38%)
Amylyx Pharmaceuticals Announces Donated CENTAUR Clinical Trial Data Now Available to Help Advance Science in ALS for Future Treatments and Discoveries

Amylyx Pharmaceuticals, Inc. today announced that the donated clinical data from the placebo arm of the CENTAUR clinical trial that evaluated the safety, efficacy, and survival benefits of AMX0035 in adult...

AMLX : 29.77 (+1.85%)
This Stock Has Delivered a Gain of 100% Over the Past 3 Months. Can You Still Buy?

Amylyx Pharmaceuticals has just one drug in its pipeline -- but it's for ALS, and the available treatments for that disease leave much to be desired.

AMLX : 29.77 (+1.85%)
Amylyx Pharmaceuticals Announces Publication of Preclinical Data Showing Potential Synergistic Effect of AMX0035 Compared to Individual Compounds

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the publication of preclinical data showing the effect of sodium phenylbutyrate (PB) and taurursodiol (TURSO,...

AMLX : 29.77 (+1.85%)
Does a Revolutionary New ALS Drug Make This Biotech Stock a Buy Now?

The FDA will most likely approve this company's first drug, but what comes next is more difficult to predict.

AMLX : 29.77 (+1.85%)
Amylyx (AMLX) Up 51% After FDA Committee Endorses ALS Drug

The FDA's PCNSDAC recommends granting marketing approval to Amylyx's (AMLX) oral drug, which slows the progression of ALS.

KMDA : 4.43 (-1.56%)
AMLX : 29.77 (+1.85%)
SESN : 0.3887 (-0.59%)
MORF : 27.90 (-3.02%)
Why Amylyx Pharmaceuticals Stock Is on Fire Today

The drugmaker's ALS drug got a thumbs-up from a panel of experts yesterday.

AMLX : 29.77 (+1.85%)
Amylyx Pharmaceuticals Announces FDA Advisory Committee Supports Approval of AMX0035 for the Treatment of ALS

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) announced today that the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs Advisory...

AMLX : 29.77 (+1.85%)
Amylyx Pharmaceuticals Stock Trading Halted Today

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that Nasdaq has halted trading of the Company’s common stock.

AMLX : 29.77 (+1.85%)

Business Summary

Amylyx Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. It focuses on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. Amylyx Pharmaceuticals Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 30.78
2nd Resistance Point 30.14
1st Resistance Point 29.68
Last Price 29.77
1st Support Level 28.59
2nd Support Level 27.95
3rd Support Level 27.49

See More

52-Week High 33.41
Last Price 29.77
Fibonacci 61.8% 23.13
Fibonacci 50% 19.96
Fibonacci 38.2% 16.79
52-Week Low 6.51

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar